Literature DB >> 27822416

Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas.

Takahiro Isono1, Tokuhiro Chano2, Tetsuya Yoshida3, Susumu Kageyama3, Akihiro Kawauchi3, Masafumi Suzaki1, Takeshi Yuasa4.   

Abstract

Dormant cancer cells are deprivation-resistant, and cause a number of problems for therapeutic approaches for cancers. Renal cell carcinomas (RCCs) include deprivation-resistant cells that are resistant to various treatments. In this study, the specific characteristics of deprivation-resistant cells were transcriptionally identified by next generation sequencing. The hypoxia-inducible factors (HIF) transcription factor network was significantly enhanced in deprivation-resistant RCCs compared to the sensitive RCCs. Deprivation-resistant RCCs, that had lost Von Hippel-Lindau tumor suppressor expression, expressed hydroxyl-HIF2-alpha in the nucleus, but not sensitive-RCCs. Hydroxyl-HIF-alpha was also expressed in nuclei of RCC tissue samples. Knockdown for HIF2-alpha, but not HIF1-alpha, induced cell death related to a reduction in HIF-related gene expression in deprivation-resistant RCC cells. Chetomin, a nuclear HIF-inhibitor, induced marked level of cytotoxicity in deprivation-resistant cells, similar to the knockdown of HIF2-alpha. Therefore, hydroxyl-HIF2-alpha might be a potential therapeutic target for RCCs.

Entities:  

Keywords:  HIF2-alpha; Hypoxia-inducible factors (HIF); POU5F1; Von Hippel-Lindau (VHL); chetomin; deprivation; global transcriptome; hydroxyl-HIF-alpha; next generation sequencer (NGS); renal cell carcinoma (RCC)

Year:  2016        PMID: 27822416      PMCID: PMC5088290     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  23 in total

1.  Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases.

Authors:  Bhuvaneswari Krishnan; Luan D Truong
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Authors:  Mei Yee Koh; Vuvi Nguyen; Robert Lemos; Bryant G Darnay; Galina Kiriakova; Mena Abdelmelek; Thai H Ho; Jose Karam; Federico A Monzon; Eric Jonasch; Garth Powis
Journal:  Cancer Res       Date:  2014-11-24       Impact factor: 12.701

Review 5.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

6.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Authors:  Olivier Rixe; Ronald M Bukowski; M Dror Michaelson; George Wilding; Gary R Hudes; Oliver Bolte; Robert J Motzer; Paul Bycott; Katherine F Liau; James Freddo; Peter C Trask; Sinil Kim; Brian I Rini
Journal:  Lancet Oncol       Date:  2007-10-23       Impact factor: 41.316

7.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

10.  Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Authors:  Kelie M Reece; Emily D Richardson; Kristina M Cook; Tessa J Campbell; Stephen T Pisle; Alesia J Holly; David J Venzon; David J Liewehr; Cindy H Chau; Douglas K Price; William D Figg
Journal:  Mol Cancer       Date:  2014-04-28       Impact factor: 27.401

View more
  6 in total

1.  Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy.

Authors:  James A Votava; Shannon R Reese; Kathryn M Deck; Christopher P Nizzi; Sheila A Anderson; Arjang Djamali; Richard S Eisenstein
Journal:  Am J Physiol Renal Physiol       Date:  2021-11-29

Review 2.  Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.

Authors:  Bingran Wang; Yizheng Xue; Wei Zhai
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  DEAD Box Protein Family Member DDX28 Is a Negative Regulator of Hypoxia-Inducible Factor 2α- and Eukaryotic Initiation Factor 4E2-Directed Hypoxic Translation.

Authors:  Sonia L Evagelou; Olivia Bebenek; Erin J Specker; James Uniacke
Journal:  Mol Cell Biol       Date:  2020-02-27       Impact factor: 4.272

4.  Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas.

Authors:  Takahiro Isono; Tokuhiro Chano; Tetsuya Yoshida; Susumu Kageyama; Akihiro Kawauchi; Junji Yonese; Takeshi Yuasa
Journal:  Oncotarget       Date:  2018-05-01

5.  Analysis of the characteristics of chemotherapy-resistant renal cell carcinomas based on global transcriptional analysis of their tissues and cell lines.

Authors:  Takahiro Isono; Masafumi Suzaki
Journal:  PLoS One       Date:  2019-11-27       Impact factor: 3.240

6.  HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells.

Authors:  Eloy Moreno Roig; Arjan J Groot; Ala Yaromina; Tessa C Hendrickx; Lydie M O Barbeau; Lorena Giuranno; Glenn Dams; Jonathan Ient; Veronica Olivo Pimentel; Marike W van Gisbergen; Ludwig J Dubois; Marc A Vooijs
Journal:  Cells       Date:  2019-01-12       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.